Selegiline in treatment of behavioral and cognitive symptoms of Alzheimer disease (Q41317848)

29 September 2017

1 reference

title

Selegiline in treatment of behavioral and cognitive symptoms of Alzheimer disease (English)

1 reference

29 September 2017

0 references

S R Tolbert

1

1 reference

29 September 2017

M A Fuller

series ordinal

2

1 reference

29 September 2017

language of work or name

English

0 references

publication date

1 October 1996

1 reference

Annals of Pharmacotherapy

29 September 2017

published in

1 reference

29 September 2017

volume

30

1 reference

29 September 2017

issue

10

1 reference

29 September 2017

page(s)

1122-1129

1 reference

The de facto US mental and addictive disorders service system. Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services

29 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001012

An epidemiologist views senile dementia--facts and fragments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001012

Overview of depression and psychosis in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001012

Troublesome and disruptive behaviors in dementia. Relationships to diagnosis and disease severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001012

Behavioral disturbance in dementia of the Alzheimer's type.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001012

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001012

A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001012

Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001012

Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. Groupe Français d'Etude de la Tetrahydroaminoacridine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001012

Tetrahydroaminoacridine-lecithin combination treatment in patients with intermediate-stage Alzheimer's disease. Results of a Canadian double-blind, crossover, multicenter study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001012

Tacrine in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001012

Alzheimer Disease: Basic and Clinical Advances

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001012

Ageing, monoamines, and monoamine-oxidase levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001012

Brain and brain monoamine oxidase in aging and in dementia of Alzheimer's type

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001012

Platelet monamine oxidase in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001012

Changes in the brain catecholamines in patients with dementia of Alzheimer type.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001012

Dopamine in Alzheimer's disease and senile dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001012

Selective loss of neurones of origin of adrenergic projection to cerebral cortex (nucleus locus coeruleus) in senile dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001012

Neuropathological and biochemical observations on the noradrenergic system in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001012

Cell loss in the locus coeruleus in senile dementia of Alzheimer type.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001012

Biochemical changes in dementia disorders of Alzheimer type (AD/SDAT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001012

Loss of pigmented dopamine-beta-hydroxylase positive cells from locus coeruleus in senile dementia of Alzheimer's type

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001012

Changes of Biogenic Amines and Their Metabolites in Postmortem Brains from Patients with Alzheimer-Type Dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001012

Alzheimer's disease and senile dementia: biochemical characteristics and aspects of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001012

Impaired Learning and Decreased Cortical Norepinephrine after Bilateral Locus Coeruleus Lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001012

Catecholamine theories of reward: A critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001012

The pharmacology of memory: a neurobiological perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001012

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001012

Mesocortical dopaminergic function and human cognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001012

Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001012

Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001012

Deprenyl protects dopamine neurons from the neurotoxic effect of 1-methyl-4-phenylpyridinium ion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001012

Brief information on an early phase-II study with deprenyl in demented patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001012

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001012

The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001012

Effects of a MAO-B inhibitor in the treatment of Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001012

L-deprenyl in the treatment of mild dementia of the Alzheimer type: preliminary results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001012

L-deprenyl in the treatment of mild dementia of the Alzheimer type: results of a 15-month trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001012

L-deprenyl in Alzheimer's disease. Preliminary evidence for behavioral change with monoamine oxidase B inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001012

Cognitive effects of L-deprenyl in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001012

Alzheimer-type dementia and verbal memory performances: influence of selegiline therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001012

CBF and cognitive evaluation of Alzheimer type patients before and after IMAO-B treatment: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001012

A double-blind crossover pilot study of l-deprenyl (selegiline) combined with cholinesterase inhibitor in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001012

A new scale for clinical assessment in geriatric populations: Sandoz Clinical Assessment--Geriatric (SCAG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001012

Cornell Scale for Depression in Dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001012

A new scale for the assessment of depressed mood in demented patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001012

A new rating scale for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001012

Reliability of the Washington University Clinical Dementia Rating.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001012

Mild senile dementia of Alzheimer type: research diagnostic criteria, recruitment, and description of a study population

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001012

A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001012

A Standardized Memory Scale for Clinical Use

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603001012

10.1177/106002809603001012

21 January 2018

Identifiers

DOI

1 reference

29 September 2017

1 reference